This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transfemoral TAVR by the Houston Methodist TAVR Team
Transcatheter aortic valve replacement (TAVR) is changing the landscape of the treatment of structural heart disease. There are now more TAVRs than isolated surgical AVRs done in the USA. The authors believe it is crucial for cardiac surgeons to be full partners in this procedure. To do so, surgeons need to understand the valves and the technical aspects of their use. This video introduces the cardiac surgeon to transfemoral TAVR as done by the TAVR team at Houston Methodist in Texas, USA.
- Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63(19):1972-1981.
- Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790-1798.
- Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14):1321-1331.
Dr Reardon is the national surgical primary investigator for the Medtronic SURTAVI and low risk trials, and he is a consultant for Medtronic and Boston Scientific.